Replimune in the spotlight: Earnings loom days after FDA approval

Replimune Group Inc. will release its fourth-quarter earnings on Monday, August 10, marking the company's first results after receiving FDA approval for its melanoma therapy just three days earlier. Despite the approval breakthrough on August 6, the company remains pre-revenue as patients must try and fail immune therapy before considering Tudriqev (vusolimogene oderparepvec-wtpg).

Analysts expect a loss of $0.65 per share and zero revenue for the quarter ending June 30, 2026, reflecting a narrower loss compared to the prior quarter's actual loss of $0.76 per share. Revenue estimates have remained flat at zero, while the consensus price target of $19.33 implies a 50% upside from the current $12.86 share price.

Commercial readiness is a major concern for investors, with uncertainty surrounding manufacturing and commercial infrastructure rebuilding post-approval. Management will be under pressure to provide clarity on launch timelines, sales force deployment, and physician adoption during the earnings call. The confirmatory Phase 3 IGNYTE-3 trial's progress, with results expected in 2027, will also impact investor confidence.